# Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis

> **NCT03778008** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 90 (estimated)

## Conditions studied

- Stomatitis

## Interventions

- **DRUG:** Recombinant bovine basic fibroblast growth factor
- **COMBINATION_PRODUCT:** Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition

## Key facts

- **NCT ID:** NCT03778008
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-21
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778008, "Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03778008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*